These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 25831219

  • 1. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.
    Habtewold A, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, Burhenne J, Aklillu E.
    Pharmacogenomics; 2015; 16(10):1047-64. PubMed ID: 25831219
    [Abstract] [Full Text] [Related]

  • 2. CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.
    Mukonzo JK, Nanzigu S, Waako P, Ogwal-Okeng J, Gustafson LL, Aklillu E.
    Pharmacogenomics; 2014 Aug; 15(11):1423-35. PubMed ID: 25303294
    [Abstract] [Full Text] [Related]

  • 3. CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.
    Mukonzo JK, Bisaso RK, Ogwal-Okeng J, Gustafsson LL, Owen JS, Aklillu E.
    Pharmacogenomics; 2016 Apr; 17(6):603-13. PubMed ID: 27045425
    [Abstract] [Full Text] [Related]

  • 4. Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
    Mugusi S, Ngaimisi E, Janabi M, Mugusi F, Minzi O, Aris E, Bakari M, Bertilsson L, Burhenne J, Sandstrom E, Aklillu E.
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1405-1415. PubMed ID: 30003275
    [Abstract] [Full Text] [Related]

  • 5. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
    Mukonzo JK, Okwera A, Nakasujja N, Luzze H, Sebuwufu D, Ogwal-Okeng J, Waako P, Gustafsson LL, Aklillu E.
    BMC Infect Dis; 2013 Jun 04; 13():261. PubMed ID: 23734829
    [Abstract] [Full Text] [Related]

  • 6. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, Prommool V, Ruxrungtham K, N2R Study Team.
    Clin Infect Dis; 2009 Jun 15; 48(12):1752-9. PubMed ID: 19438397
    [Abstract] [Full Text] [Related]

  • 7. Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
    Habtewold A, Aklillu E, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, Owen JS, Burhenne J.
    J Clin Pharmacol; 2016 Dec 15; 56(12):1538-1549. PubMed ID: 27125860
    [Abstract] [Full Text] [Related]

  • 8. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
    Friedland G, Khoo S, Jack C, Lalloo U.
    J Antimicrob Chemother; 2006 Dec 15; 58(6):1299-302. PubMed ID: 17032686
    [Abstract] [Full Text] [Related]

  • 9. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.
    Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Bertilsson L, Burhenne J, Aklillu E.
    Clin Pharmacol Ther; 2011 Sep 15; 90(3):406-13. PubMed ID: 21814190
    [Abstract] [Full Text] [Related]

  • 10. Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations.
    Mugusi S, Habtewold A, Ngaimisi E, Amogne W, Yimer G, Minzi O, Makonnen E, Sudfeld C, Burhenne J, Aklillu E.
    Front Pharmacol; 2020 Sep 15; 11():26. PubMed ID: 32116703
    [Abstract] [Full Text] [Related]

  • 11. Efavirenz Plasma Concentrations and HIV Viral Load in HIV/AIDS-tuberculosis Infection Patients Treated with Rifampicin.
    Mariana N, Purwantyastuti, Instiaty, Rusli A.
    Acta Med Indones; 2016 Jan 15; 48(1):10-6. PubMed ID: 27241539
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.
    Ngaimisi E, Minzi O, Mugusi S, Sasi P, Riedel KD, Suda A, Ueda N, Bakari M, Janabi M, Mugusi F, Bertilsson L, Burhenne J, Aklillu E, Diczfalusy U.
    J Antimicrob Chemother; 2014 Dec 15; 69(12):3311-9. PubMed ID: 25096076
    [Abstract] [Full Text] [Related]

  • 13. Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.
    Naidoo A, Chirehwa M, McIlleron H, Naidoo K, Essack S, Yende-Zuma N, Kimba-Phongi E, Adamson J, Govender K, Padayatchi N, Denti P.
    J Antimicrob Chemother; 2017 May 01; 72(5):1441-1449. PubMed ID: 28175315
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R, Musaazi J, Denti P, Aber F, Lamorde M, Dooley KE, Aarnoutse R, Sloan DJ, Sekaggya-Wiltshire C.
    Trials; 2020 Feb 13; 21(1):181. PubMed ID: 32054536
    [Abstract] [Full Text] [Related]

  • 15. Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing.
    Alghamdi WA, Antwi S, Enimil A, Yang H, Dompreh A, Wiesner L, Langaee T, Peloquin CA, Kwara A.
    J Antimicrob Chemother; 2019 Sep 01; 74(9):2698-2706. PubMed ID: 31243456
    [Abstract] [Full Text] [Related]

  • 16. High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.
    von Braun A, Castelnuovo B, Ledergerber B, Cusato J, Buzibye A, Kambugu A, Fehr J, Calcagno A, Lamorde M, Sekaggya-Wiltshire C.
    J Antimicrob Chemother; 2019 Jan 01; 74(1):135-138. PubMed ID: 30239753
    [Abstract] [Full Text] [Related]

  • 17. Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.
    Sathia L, Obiorah I, Taylor G, Kon O, O'Donoghue M, Gibbins S, Walsh J, Winston A.
    AIDS Res Hum Retroviruses; 2008 Jul 01; 24(7):897-901. PubMed ID: 18671475
    [Abstract] [Full Text] [Related]

  • 18. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
    Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S.
    HIV Med; 2008 May 01; 9(5):294-9. PubMed ID: 18400076
    [Abstract] [Full Text] [Related]

  • 19. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1.
    Patel A, Patel K, Patel J, Shah N, Patel B, Rani S.
    J Acquir Immune Defic Syndr; 2004 Sep 01; 37(1):1166-9. PubMed ID: 15319677
    [Abstract] [Full Text] [Related]

  • 20. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?
    Orrell C, Cohen K, Conradie F, Zeinecker J, Ive P, Sanne I, Wood R.
    Antivir Ther; 2011 Sep 01; 16(4):527-34. PubMed ID: 21685540
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.